Orphenadrine Citrate

Muscle Pain, Bursitis, Pain + 17 more

Treatment

7 FDA approvals

20 Active Studies for Orphenadrine Citrate

What is Orphenadrine Citrate

Orphenadrine

The Generic name of this drug

Treatment Summary

Caffeine is a drug used to treat various conditions, such as respiratory issues in premature newborns, pain relief, and drowsiness. It is similar in chemical structure to Theophylline and Theobromine and can be sourced from coffee beans, teas, and cacao beans. Caffeine is also found in a variety of cosmetic products and can be taken orally, through inhalation, or via injection. In 1999, the FDA approved the use of caffeine citrate injection to treat apnea of the premature newborn. Caffeine helps to prevent and treat apnea and bronchopulmonary dysplasia

Norflex

is the brand name

image of different drug pills on a surface

Orphenadrine Citrate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Norflex

Orphenadrine

1959

68

Approved as Treatment by the FDA

Orphenadrine, otherwise called Norflex, is approved by the FDA for 7 uses which include Muscle Spasms and Musculoskeletal Diseases .

Muscle Spasms

Musculoskeletal Diseases

Used to treat mild Musculoskeletal Disorder in combination with Acetylsalicylic acid

other pain relief measures

Used to treat other pain relief measures in combination with Acetylsalicylic acid

Physical Therapy

Used to treat Physical Therapy in combination with Acetylsalicylic acid

Rest

Used to treat Rest in combination with Acetylsalicylic acid

Spasm

Musculoskeletal Diseases

Used to treat moderate Musculoskeletal Disorder in combination with Acetylsalicylic acid

Effectiveness

How Orphenadrine Citrate Affects Patients

Caffeine wakes up the brain and body, making you more alert and often resulting in feeling jittery. It can also help relax muscles, make the heart beat faster, and improve athletic performance. Caffeine also increases the production of stomach acid and helps speed up digestive activities. It is often used in combination with pain relievers to help with migraine and other types of headaches. As a bonus, caffeine can act as a mild diuretic.

How Orphenadrine Citrate works in the body

Caffeine affects many parts of the body. It works by blocking certain enzymes and molecules, which can help keep you awake, increase your alertness, and stimulate your heart and blood vessels. In the cells, it helps regulate calcium and lipolysis, which is the breakdown of fat. In the respiratory system, it increases your breathing rate and helps you take in oxygen more efficiently. In the central nervous system, it blocks receptors that promote drowsiness. In the kidneys, it causes you to urinate more frequently. Finally, in the cardiovascular system, it causes blood vessels to relax, increases blood flow, and can raise your

When to interrupt dosage

The prescribed dosage of Orphenadrine Citrate is conditioned by the evaluated disorder, such as Overdose, Drug, Catarrh and Athletic Performance. The measure of dosage can be located in the below table, contingent on the delivery modality (e.g. Tablet or Tablet - Oral).

Condition

Dosage

Administration

Muscle Pain

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Fever

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Sprains and Strains

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Musculoskeletal Diseases

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Wounds and Injuries

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Muscle Strain

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Mild pain

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Pain

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Inflammation

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Musculoskeletal Diseases

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Musculoskeletal Diseases

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

other pain relief measures

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Bursitis

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Pain

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Physical Therapy

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Rheumatism

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Rest

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Dysmenorrhea

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Spasm

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Low Back Pain

30.0 mg/mL, , 100.0 mg, 50.0 mg, 25.0 mg, 60.0 mg/mL

Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, , Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Tablet, Tablet - Oral, Liquid, Liquid - Intramuscular; Intravenous

Warnings

Orphenadrine Citrate Contraindications

Condition

Risk Level

Notes

Prostatic Hyperplasia

Do Not Combine

Peptic Ulcer

Do Not Combine

Duodenal Obstruction

Do Not Combine

Esophageal Achalasia

Do Not Combine

Pyloric Stenosis

Do Not Combine

Open-angle glaucoma

Do Not Combine

Urinary Bladder Neck Obstruction

Do Not Combine

Myasthenia Gravis

Do Not Combine

There are 20 known major drug interactions with Orphenadrine Citrate.

Common Orphenadrine Citrate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Orphenadrine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Orphenadrine.

Acebutolol

Major

The metabolism of Acebutolol can be decreased when combined with Orphenadrine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Orphenadrine is combined with Aclidinium.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Orphenadrine.

Orphenadrine Citrate Toxicity & Overdose Risk

Consuming too much caffeine can be dangerous. In rats, the toxic dose of caffeine is 192mg/kg. In humans, an overdose is considered to be around 10-14 grams (roughly 150-200mg/kg of body weight). Symptoms of overdose may include nausea, vomiting, diarrhea, restlessness, insomnia, heart palpitations, anxiety, and agitation. More severe symptoms such as seizures, psychomotor agitation, and death are possible depending on the amount of caffeine consumed. To treat a mild caffeine overdose, symptomatic treatment should be provided. In severe cases, emergency treatment such as intubation, activated charcoal

image of a doctor in a lab doing drug, clinical research

Orphenadrine Citrate Novel Uses: Which Conditions Have a Clinical Trial Featuring Orphenadrine Citrate?

429 active trials are investigating the potential of Orphenadrine Citrate to combat Chronic Fatigue Syndrome, Chronic Pain and Migraine.

Condition

Clinical Trials

Trial Phases

Musculoskeletal Diseases

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Mild pain

0 Actively Recruiting

Rest

0 Actively Recruiting

Wounds and Injuries

7 Actively Recruiting

Not Applicable, Phase 3

Rheumatism

0 Actively Recruiting

other pain relief measures

0 Actively Recruiting

Spasm

0 Actively Recruiting

Sprains and Strains

0 Actively Recruiting

Pain

0 Actively Recruiting

Pain

0 Actively Recruiting

Muscle Pain

3 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Inflammation

0 Actively Recruiting

Bursitis

0 Actively Recruiting

Musculoskeletal Diseases

0 Actively Recruiting

Low Back Pain

8 Actively Recruiting

Not Applicable, Phase 4, Phase 1

Muscle Strain

0 Actively Recruiting

Physical Therapy

6 Actively Recruiting

Not Applicable

Musculoskeletal Diseases

0 Actively Recruiting

Orphenadrine Citrate Reviews: What are patients saying about Orphenadrine Citrate?

5

Patient Review

7/21/2014

Orphenadrine Citrate for Muscle Spasm

After my third surgery on my left foot, I experienced some very intense muscle spasms.

5

Patient Review

4/9/2016

Orphenadrine Citrate for Muscle Spasm

I was dealing with a really bad spasm in my rhomboid muscle and this treatment completely relieved it.

4.3

Patient Review

7/14/2013

Orphenadrine Citrate for Muscle Spasm

This medication effectively alleviated my back muscle spasms; however, I began experiencing anxiety attacks and vivid dreams.

4.3

Patient Review

11/2/2013

Orphenadrine Citrate for Muscle Spasm

While this treatment didn't exactly relieve my spasms as I'd hoped, it did help me avoid having to take painkillers.

4.3

Patient Review

10/1/2012

Orphenadrine Citrate for Muscle Spasm

4

Patient Review

5/12/2014

Orphenadrine Citrate for Muscle Spasm

I really appreciate how this product is not invasive.

3.7

Patient Review

1/3/2013

Orphenadrine Citrate for Muscle Spasm

3.7

Patient Review

6/28/2013

Orphenadrine Citrate for Muscle Spasm

3.3

Patient Review

2/9/2013

Orphenadrine Citrate for Muscle Spasm

3.3

Patient Review

5/11/2013

Orphenadrine Citrate for Muscle Spasm

3

Patient Review

5/18/2012

Orphenadrine Citrate for Muscle Spasm

2.7

Patient Review

5/5/2016

Orphenadrine Citrate for Muscle Spasm

I experienced muscle spasms in my neck and left arm.

2.3

Patient Review

1/22/2013

Orphenadrine Citrate for Muscle Spasm

2

Patient Review

7/31/2013

Orphenadrine Citrate for Muscle Spasm

I was prescribed this medication for back strain, but saw no relief even after taking the full course. Additionally, the naproxen and norco made me nauseous.

1

Patient Review

1/11/2020

Orphenadrine Citrate for Muscle Spasm

Unfortunately, this drug has made my anxiety worse and caused restless legs syndrome. On top of that, it's actually increased the pain I was already experiencing.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about orphenadrine citrate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does orphenadrine make you sleep?

"Some of the dosage forms listed on this page may not apply to the brand name Orphenadrine..

Orphenadrine may cause drowsiness as well as other side effects. Some of the listed dosage forms may not apply to the brand name Orphenadrine."

Answered by AI

What is orphenadrine citrate used for?

"Orphenadrine is a medication used to help relax muscles and relieve stiffness, pain, and discomfort caused by strains, sprains, or other injuries. One form of orphenadrine is also used to relieve trembling caused by Parkinson's disease."

Answered by AI

What is orphenadrine side effect?

"The following side effects may occur: dry mouth, dizziness, drowsiness, lightheadedness, blurred vision, nausea, vomiting, and constipation. If you experience any of these effects for an extended period of time, or if they worsen, contact your doctor or pharmacist."

Answered by AI

Is orphenadrine citrate a painkiller?

"Norgesic consists of a muscle relaxant, a pain reliever, and caffeine. It is usually used in conjunction with rest and physical therapy to treat injuries and other painful muscular conditions. Caffeine increases the pain relieving effects of the other drugs."

Answered by AI

Clinical Trials for Orphenadrine Citrate

Image of St. John's Rehab at Sunnybrook in Toronto, Canada.

Peer Support Program for Traumatic Injury

18+
All Sexes
Toronto, Canada

Traumatic injuries from events like car crashes, falls, or fires are a leading cause of disability. Survivors often face not only physical challenges but also long-lasting pain, mental health challenges and difficulty returning to work and family life. Although medical care focuses on physical recovery, survivors frequently report that their emotional and social needs are overlooked and unmet. Peer support-guidance from people who have lived through similar injuries-can reduce distress and improve coping. However, no programs in Canada currently provide peer support to trauma survivors across their recovery journey, from hospital to rehabilitation to community living. The investigators worked with trauma survivors, caregivers, and healthcare providers to co-design a Peer Support Program (PSP) that offers support throughout these stages. This pilot study will test whether the program is feasible and acceptable, and explore its early impact on recovery. Results will guide a future larger trial to expand peer support in trauma care.

Waitlist Available
Has No Placebo

St. John's Rehab at Sunnybrook (+1 Sites)

Marina Wasilewski, PhD

Image of Medical University of South Carolina in Charleston, United States.

SPRINT PNS System for Lower Back Pain

18+
All Sexes
Charleston, SC

Chronic lower back pain is a significant cause of disability, affecting 21-68% of people 60 years of age and older (source). Of these cases, 15-30% are attributed to posterior sacroiliac joint complex (PSIJC) pain (source), making it a target for treatment. Peripheral Nerve Stimulation (PNS) is a procedure that involves the placement of a lead under the skin with local anesthetic and electrically stimulating designated spinal nerves that deliver pain signals to the brain. It has emerged as a promising alternative to drug, injection, and radioablative therapies. Its use has been supported by previous studies of subjects who received permanent neurostimulation and experienced benefits such as decreased sensation of pain and perceived level of disability. SPRINT is a minimally invasive PNS system of interest due to its ability to provide long-term pain relief after temporary administration of PNS. The aim of this study is to understand whether the FDA-cleared SPRINT PNS system is safe and effective for the treatment of chronic PSIJC pain. This prospective clinical study will assess 10 subjects that meet the inclusion and exclusion criteria across 5 separate time points- 1.) Screening; 2.) Procedure within 3 months of screening; 3.) 12-day post-procedure follow-up; 4.) 3-month post-procedure follow-up; 5.) 3-Month post lead removal follow-up. The subjects will be required to complete physical examinations, and VAS and ODI questionnaires at timepoints 3, 4, and 5.

Recruiting
Has No Placebo

Medical University of South Carolina

Ameet Nagpal

SPR Therapeutics, Inc.

Have you considered Orphenadrine Citrate clinical trials?

We made a collection of clinical trials featuring Orphenadrine Citrate, we think they might fit your search criteria.
Go to Trials
Image of Walter Reed National Military Medical Center in Bethesda, United States.

Corticosteroid Injections for Osteoarthritis

18+
All Sexes
Bethesda, MD

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

Phase 2 & 3
Waitlist Available

Walter Reed National Military Medical Center

John P Cody, MD

Image of Rutgers School of Dental Medicine in Newark, United States.

Temporo-masseteric Nerve Block for Postoperative Pain

18+
All Sexes
Newark, NJ

The proposed design is a triple-blind, placebo-controlled randomized prospective phase II trial to assess the feasibility of employing the Temporo-masseteric Nerve Block (TMNB) injection to decrease jaw muscle pain, overall pain, improve mouth opening and minimize pain medication consumption. 80 participants undergoing lower third molar removal under sedation will be enrolled. Those who develop significant jaw muscle pain on the following day will be randomized to receive either the TMNB injection or a placebo. Daily ecological momentary assessments (EMAs) will be collected reflecting elements of patient experience for all participants. On Day 8, participants return for an end-of-study evaluation and return their unused pain medications. Up to 40 participants who are randomized to receive TMNB/placebo will be recruited to participate in a qualitative interview regarding their experience.

Phase 2
Waitlist Available

Rutgers School of Dental Medicine

Have you considered Orphenadrine Citrate clinical trials?

We made a collection of clinical trials featuring Orphenadrine Citrate, we think they might fit your search criteria.
Go to Trials
Image of School of Allied Health Professions in Loma Linda, United States.

Seed Cycling for Menstrual Disorder

18 - 45
Female
Loma Linda, CA

The purpose of this research is to investigate the impact of seed cycling on menstrual regularity, cramps, and pre-menstrual symptoms in women with an irregular menstrual cycle and/or dysmenorrhea. The research seeks to provide evidence-based insights into the potential benefits of seed cycling as a holistic approach to women's reproductive health. It is expected that your participation will last 3 months. Procedures and Activities. You will be provided with and asked to consume specific seeds daily. The seeds are to be consumed as follows: follicular phase (the period from the first day of menstruation (day 1) to ovulation (day 14) in a typical 28-day cycle): 1 tablespoon flax seeds and 1 tablespoon pumpkin seeds, and luteal phase (the period between ovulation and the start of the next period; typically days 15-28): 1 tablespoon sunflower seeds and 1 tablespoon sesame seeds. Before the intervention and once monthly for a total of 3 cycles, you will be asked to complete an online menstrual health symptom questionnaire (MHSQ) and keep track of your menstrual cycle days on the built-in health tracking app on your electronic device. Risks. Some of the foreseeable risks or discomforts of your participation include the potential for mild gastrointestinal side effects, the potential for allergic reactions, and the possibility of no significant benefit. Benefits. Possible benefits include the potential for improved menstrual cycle regularity, the potential for a reduction in premenstrual syndrome (PMS) symptoms, and the potential for nutritional benefits. Societal benefits include additional knowledge on seed cycling to help manage menstrual regularity and PMS symptoms.

Waitlist Available
Has No Placebo

School of Allied Health Professions

Have you considered Orphenadrine Citrate clinical trials?

We made a collection of clinical trials featuring Orphenadrine Citrate, we think they might fit your search criteria.
Go to Trials